Compare Stocks → New Options need New Trading Strategies (From Netpicks) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:PEPGNASDAQ:SRPT Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePEPGPepGen$13.89$13.15$3.72▼$17.51$450.31M1.64104,641 shs6,272 shsSRPTSarepta Therapeutics$128.87-0.2%$126.83$55.25▼$150.16$12.18B0.951.01 million shs12,864 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePEPGPepGen+2.97%-0.71%+31.85%+1.76%-3.54%SRPTSarepta Therapeutics-1.31%-2.67%+11.68%-2.40%-13.38%This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industryMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationPEPGPepGen1.868 of 5 stars3.52.00.00.01.91.70.6SRPTSarepta Therapeutics4.7772 of 5 stars4.41.00.04.23.22.51.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePEPGPepGen3.00Buy$24.6777.59% UpsideSRPTSarepta Therapeutics2.86Moderate Buy$163.9427.21% UpsideCurrent Analyst RatingsLatest PEPG and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2024SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$166.005/17/2024SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$145.00 ➝ $179.005/15/2024PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.005/15/2024PEPGPepGenWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$20.005/14/2024SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$180.005/3/2024SRPTSarepta TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$177.00 ➝ $175.005/2/2024SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$128.005/2/2024SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$166.003/7/2024PEPGPepGenWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.003/1/2024SRPTSarepta TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$164.00 ➝ $167.002/29/2024SRPTSarepta TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$128.00(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPEPGPepGenN/AN/AN/AN/A$5.52 per shareN/ASRPTSarepta Therapeutics$1.24B9.80N/AN/A$10.17 per share12.67Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePEPGPepGen-$78.63M-$3.25N/AN/AN/AN/A-57.32%-46.14%8/13/2024 (Estimated)SRPTSarepta Therapeutics-$535.98M$0.111,171.5516.15N/A1.20%2.20%0.58%8/7/2024 (Estimated)Latest PEPG and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2024Q1 24SRPTSarepta Therapeutics-$0.11$0.73+$0.84$0.39$375.52 million$413.50 million 3/6/2024Q4 2023PEPGPepGen-$1.01-$0.82+$0.19-$0.82N/AN/A2/28/2024Q4 23SRPTSarepta Therapeutics-$0.03$0.47+$0.50$0.47$387.18 million$396.80 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPEPGPepGenN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPEPGPepGenN/A15.7815.78SRPTSarepta Therapeutics1.184.053.44OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPEPGPepGen58.01%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipPEPGPepGen4.60%SRPTSarepta Therapeutics7.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionablePEPGPepGen6432.42 million30.93 millionNot OptionableSRPTSarepta Therapeutics1,31494.52 million87.25 millionOptionablePEPG and SRPT HeadlinesRecent News About These CompaniesMay 22 at 9:06 AM | benzinga.comJim Cramer: This Industrial Stock Is Doing 'Very Well'; Here's His Take On PalantirMay 22 at 1:36 AM | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)May 21 at 11:24 AM | marketbeat.comTraders Buy High Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)May 21 at 3:38 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Receives "Buy" Rating from Needham & Company LLCMay 21 at 2:46 AM | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Moderate Buy" by BrokeragesMay 20 at 12:53 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and Sol-Gel Technologies (SLGL)May 20 at 12:53 PM | markets.businessinsider.com12 Analysts Have This To Say About Sarepta TherapeuticsMay 20 at 8:17 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Rating Reiterated by Needham & Company LLCMay 19 at 7:49 PM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Lifted by Mizuho Markets Americas LLCMay 19 at 4:00 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given New $179.00 Price Target at MizuhoMay 17, 2024 | markets.businessinsider.comBuy Rating for Sarepta Therapeutics’ Elevidys Supported by Positive Regulatory SignalsMay 17, 2024 | marketbeat.comThornburg Investment Management Inc. Grows Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 17, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) PT Raised to $179.00 at MizuhoMay 17, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Fiera Capital CorpMay 16, 2024 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Lifted to Outperform at OppenheimerMay 15, 2024 | marketbeat.com203,882 Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Bought by First Turn Management LLCMay 14, 2024 | marketbeat.comNicholas Investment Partners LP Sells 2,084,756 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)May 14, 2024 | msn.comRoblox downgraded, Western Digital initiated: Wall Street's top analyst callsMay 14, 2024 | msn.comOppenheimer Upgrades Sarepta Therapeutics (SRPT)May 14, 2024 | msn.comSarepta upgraded at Oppenheimer on potential Elevidys label expansionMay 14, 2024 | marketbeat.comOppenheimer Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to "Outperform"New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsPepGenNASDAQ:PEPGPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Sarepta TherapeuticsNASDAQ:SRPTSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.